Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autobio Diagnostics CoSHSE:603658 -2.21%95 Pretax Margin % is 26.66% as of Jun. 2026, which is 11% below its 10-year median of 29.90. GuruFocus rates SHSE:603658 with a GF Score™ of 95/100 and a GF Value™ of ¥40.43 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Autobio Diagnostics Co ranks better than 91.78% on this metric.
The historical rank and industry rank for Autobio Diagnostics Co's Pretax Margin % or its related term are showing as below:
SHSE:603658'
s Pretax Margin % Range Over the Past 10 Years
Min: 26.75 Med: 29.9 Max: 41.6
Current: 26.75
SHSE:603658's Pretax Margin % is ranked better than 91.78% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 3.03
vs SHSE:603658: 26.75
Autobio Diagnostics Co (SHSE:603658) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Autobio Diagnostics Co Pretax Margin % Related Terms
Autobio Diagnostics Co Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Autobio Diagnostics Co's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603658 vs ABT, SYK, MDT: Pretax Margin % Comparison
For the Medical Devices subindustry, Autobio Diagnostics Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autobio Diagnostics Co Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autobio Diagnostics Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Autobio Diagnostics Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autobio Diagnostics Co (SHSE:603658) has a Pretax Margin % of 26.66% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Autobio Diagnostics Co and its competitors. This is 11% below median its historical median of 29.90. Over the past decade, Autobio Diagnostics Co's Pretax Margin % has ranged from 26.75 to 41.60. According to the industry distribution chart, Autobio Diagnostics Co ranks #67 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 8.2%.
Is Autobio Diagnostics Co's Pretax Margin % too high?
Autobio Diagnostics Co's current Pretax Margin % of 26.66% is 11% below median its 10-year median of 29.90. Over the past 10 years, this metric has ranged from a low of 26.75 to a high of 41.60. The Medical Devices & Instruments industry median Pretax Margin % is 3.03. Autobio Diagnostics Co's value of 26.66% is 779.9% above this industry median. Based on the distribution chart, Autobio Diagnostics Co ranks #67 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Autobio Diagnostics Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Autobio Diagnostics Co's Pretax Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Autobio Diagnostics Co ranks #67 out of 815 companies for Pretax Margin %. This places Autobio Diagnostics Co in the top 8% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 3.03. Autobio Diagnostics Co's value of 26.66% is 779.9% above this benchmark. Historically, Autobio Diagnostics Co's own Pretax Margin % has ranged from 26.75 to 41.60 over the past decade. While the company's 10-year median is 29.90 vs. the industry median of 3.03, Autobio Diagnostics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 3.03, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autobio Diagnostics Co's current Pretax Margin % of 26.66% is 779.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Autobio Diagnostics Co and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 3.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autobio Diagnostics Co's current Pretax Margin % is 26.66%, which is 11% below median its own 10-year median of 29.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autobio Diagnostics Co stock overvalued right now?
Based on GuruFocus' analysis, Autobio Diagnostics Co (SHSE:603658) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥40.43, compared to a current price of ¥32.67 — trading 19.2% below its estimated fair value. The current Pretax Margin % is 26.66%, which is 11% below median its 10-year median of 29.90 and 779.9% above the Medical Devices & Instruments industry median of 3.03. Autobio Diagnostics Co's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Autobio Diagnostics Co (SHSE:603658), the current Pretax Margin % is 26.66% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autobio Diagnostics Co (SHSE:603658) Overvalued in 2026?
Based on GuruFocus' analysis, Autobio Diagnostics Co stock appears to be undervalued.
The current stock price of ¥32.67 is trading 19.2% below its estimated GF Value™ of ¥40.43.
GuruFocus considers Autobio Diagnostics Co to be Modestly Undervalued.
Key valuation signals for SHSE:603658:
Pretax Margin %: 26.66% (11% below median its 10-year median of 29.90)
GF Value™: ¥40.43 vs. price of ¥32.67 (19.2% below fair value)
Industry Position: 779.9% above the Medical Devices & Instruments median (#67 of 815)
No single metric tells the full story. See the SHSE:603658 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company's main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.
95GF Score
Get the complete analysis for SHSE:603658
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603658 has been successfully added to your 
